A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
Incyte Corporation
Incyte Corporation
Dana-Farber Cancer Institute
Institute of Hematology & Blood Diseases Hospital, China
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital
Dana-Farber Cancer Institute
National Institutes of Health Clinical Center (CC)
Princess Maxima Center for Pediatric Oncology
Princess Maxima Center for Pediatric Oncology
Princess Maxima Center for Pediatric Oncology
Thomas Jefferson University
Dana-Farber Cancer Institute
UniversitƤtsklinikum Hamburg-Eppendorf
Therapeutic Advances in Childhood Leukemia Consortium
Alliance for Clinical Trials in Oncology
Therapeutic Advances in Childhood Leukemia Consortium
M.D. Anderson Cancer Center
OHSU Knight Cancer Institute
St. Jude Children's Research Hospital
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
Therapeutic Advances in Childhood Leukemia Consortium
South Plains Oncology Consortium
Gruppo Italiano Malattie EMatologiche dell'Adulto
Alliance for Clinical Trials in Oncology
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
Jonsson Comprehensive Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Therapeutic Advances in Childhood Leukemia Consortium
Wake Forest University Health Sciences
Wake Forest University Health Sciences
Nanfang Hospital, Southern Medical University
Nanfang Hospital, Southern Medical University
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Masonic Cancer Center, University of Minnesota
SWOG Cancer Research Network
OHSU Knight Cancer Institute
St. Jude Children's Research Hospital
Barbara Ann Karmanos Cancer Institute
Wake Forest University Health Sciences
Children's Oncology Group
Children's Oncology Group
Children's Oncology Group
Alliance for Clinical Trials in Oncology
Alliance for Clinical Trials in Oncology